Biotechnology
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr.Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Confe...
2025-01-14 05:43
2883
BioCina and NovaCina Merger Bolsters Global CDMO Industry
ADELAIDE, South Australia and PERTH, Western Australia, Jan. 14, 2025 /PRNewswire/ -- Global Contract Development and Manufacturing Organizations (CDMOs) BioCina and NovaCina announced a strategic merger that will create a powerful brand in biopharmaceutical and small molecule contract manufactur...
2025-01-14 00:43
3276
Dx&Vx Presents a New Paradigm for Next-Generation Infectious Disease Response with the Development of a Universal Vaccine
- Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine - Based on the Excellent Safety and Immune Response in Phase 1 Clinical Results, with a Plan to Extend Administration Routes and Indications SEOUL, South Korea, Jan. 13, 2025 /PRNe...
2025-01-13 22:00
3825
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended31 December 2024 (Q4 2024). Sustained revenue growth * Q...
2025-01-13 15:12
3972
Scintimun® Commercialization Partnership with Curium Pharma
MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99m Tc-be...
2025-01-13 13:08
2737
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next...
2025-01-13 06:34
3582
Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).
CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into an exclusive license agreement (the "License Agr...
2025-01-11 17:07
5475
Corn Next Launches CornNext-17: A Groundbreaking Sustainable Solution to Plastic Pollution
IRVINE, Calif., Jan. 11, 2025 /PRNewswire/ -- Corn Next, a leader in sustainable innovation and biodegradable solutions, has officially launched CornNext-17, a game-changing bio-based material designed to combat the global plastic pollution crisis. Accompanying this launch is the release of th...
2025-01-11 05:53
6675
JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma
SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Adm...
2025-01-10 17:00
6881
UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform
* Computational advancements enable earlier and more widespread use of antibody-antigen structural insights across drug discovery process * These advancements have the potential to transform antibody discovery methods, broadening therapeutic applications and accelerating the development of in...
2025-01-09 16:41
4590
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development
* Samsung Biologics to offer ADC services at new dedicated facility * Extended collaboration reflects successful partnership and expertise INCHEON,South Korea, Jan. 9, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO),...
2025-01-09 09:45
3548
DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu
CAMBRIDGE, England and SAN DIEGO, Jan. 9, 2025 /PRNewswire/ -- DIOSynVax, a clinical-stage biotechnology company at the forefront of developing innovative, broadly protective vaccines, built on the safety demonstrated by its "First in Human" Coronavirus vaccine trial, to announce its new portfoli...
2025-01-09 03:48
4001
Latest Updates of Viva Biotech's Portfolio Companies
HONG KONG, Jan. 8, 2025 /PRNewswire/ -- Recently, Viva Biotech's portfolio companies have new updates: TechnoDerma, VivaVision, Arthrosi, Apeiron Therapeutics and AceLink made solid progress in R&D; Full Circles published breakthrough results; Antag successfully completed financing. * TechnoDe...
2025-01-08 20:19
4069
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annualDrugs to Watc...
2025-01-08 16:12
2608
Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma
* Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI). * The partnership with IFLI will accelerate the clinical development of SynKIR™-310 in Follicular Lymphoma (FL) by leveraging IFLI's expertise and network, expanding cli...
2025-01-07 21:00
2166
Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment
TAMPA, Fla., Jan. 7, 2025 /PRNewswire/ -- Concept Medical Inc.
2025-01-07 20:14
3465
Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO and SUZHOU, China, Jan. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2025-01-06 08:00
4600
Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration
SAN FRANCISCO and SUZHOU, China, Jan. 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2025-01-03 08:00
10086
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
SAN FRANCISCO and SUZHOU, China, Jan. 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2025-01-02 07:30
11748
Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study
Further secures Brii's rights in BRII-179 with full control of intellectual property, future manufacturing and supply Several combination treatment studies containing BRII-179 have quickly started to carry forward the Company's strategy for HBV functional cure DURHAM, N.C. and BEIJING, Dec. 31, ...
2024-12-31 19:10
6054
Week's Top Stories
Most Reposted
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 300 media titles]
2026-06-04 23:55
Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 292 media titles]
2026-06-05 19:08
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 292 media titles]
2026-06-05 15:00FPT and NVIDIA Collaborate to Release the Nemotron Personas Vietnam Datasets
[Picked up by 276 media titles]
2026-06-05 17:34
Pudu Robotics and Shenzhen CTID Co. Ltd Launch the World's First Full-Scenario Robot-Serviced Hotel Project
[Picked up by 275 media titles]
2026-06-01 18:00Most Read
WePlay Korea's 4th Anniversary Celebration Kicks Off, Joining Hands with "Hello Panda-哈啰潘达" to Create Fu Bao Themed Space Decorations
2026-06-01 12:00
7838
Dreame ranked No.1 in Global Robot Vacuum Sales & Revenue, according to International Data Corporation (IDC)
2026-06-05 21:05
7318
CERAVE CELEBRATES OVER 100 AWARD-WINNING CONTENT CREATORS FROM 22 COUNTRIES FOR THE FIRST EVER GLOBAL CERAWARDS
2026-06-05 20:58
6907
